Related Experiment Video

Updated: May 22, 2026

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
10:26

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

Published on: June 2, 2015

A prospective cohort study on patients treated with anticoagulants for cerebral vein thrombosis

Maria T Sartori1, Paolo Zampieri, Sofia Barbar

  • 1Department of Cardiologic, Thoracic and Vascular Sciences, Padua University Hospital, Padova, Italy. mtsart@unipd.it

European Journal of Haematology
|May 5, 2012
PubMed

Insights

Anticoagulant therapy for cerebral vein thrombosis (CVT) shows favorable outcomes for most patients who survive the acute phase. Pulmonary embolism (PE) is common, underscoring the need for anticoagulation in CVT management.

Area of Science:

  • Neurology
  • Vascular Medicine
  • Thrombosis Research

Background:

  • Cerebral vein thrombosis (CVT) is a serious condition with limited treatment guidelines.
  • Assessing the efficacy of anticoagulant therapy in CVT patients is crucial for improving patient outcomes.

Purpose of the Study:

  • To evaluate the short- and long-term benefits of anticoagulant therapy in patients with cerebral vein thrombosis (CVT).

Main Methods:

  • A prospective cohort study involving 44 consecutive CVT patients treated with heparin followed by warfarin for at least 3 months.
  • Investigated risk factors for thrombosis, including oral contraceptive use and thrombophilia.
  • Monitored thrombotic events, hemorrhagic complications, and long-term outcomes using the modified Rankin Scale (mRS).

Main Results:

  • Risk factors for thrombosis were identified in 84.1% of patients, with high rates of oral contraceptive use and thrombophilia.
  • Pulmonary embolism (PE) was confirmed in all six patients presenting with suggestive symptoms.
  • A favorable outcome (mRS 0-2) was observed in 86% of surviving patients at 6-12 months.
  • Two patients experienced major bleeding complications, and one patient died due to CVT progression.

Conclusions:

  • Conventional anticoagulation therapy leads to favorable outcomes for the majority of CVT patients who survive the acute phase.
  • The high prevalence of concomitant pulmonary embolism (PE) in CVT patients supports the necessity of anticoagulant therapy.
Abstract

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...